<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html lang="en">

<head>
  <title>Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 - Full Text View - ClinicalTrials.gov</title>
    <meta name="robots" content="noindex,nofollow"/>
    <meta http-equiv="Content-Type" content="text/html;charset=UTF-8"/>
    <link href="/ct2/show/NCT00116012" rel="canonical"/>
    <link href="/ct2/html/images/frame/icon.ico" rel="SHORTCUT ICON"/>
  <link href="/ct2/html/images/frame/ct.css" type="text/css" rel="stylesheet"/>
  <script type="text/javascript" src="/ct2/html/images/frame/ct.js" language="JavaScript">
  </script>
</head>

<body style="min-width:720px; margin-left:0px; margin-right:0px; margin-top:0px" onload="doLoadActions();">

<!-- small_banner -->
<div class="skip"><a href="#MainContent">Skip to Main Content</a></div>

<table class="layout_table banner_color" cellspacing="0" cellpadding="0" border="0" width="100%">
  <tr>
    <td align="left" style="padding:6px" nowrap>
      <a title="Show Home Page" href="/ct2/home">
        <img alt="ClinicalTrials.gov" src="/ct2/html/images/frame/small_title.gif" border="0"/>
      </a>
    </td>

    <td class="header3" align="right" style="padding:3px 12px 3px 3px;" nowrap>
            <a style="margin-left:1em;" title="Show Home Page" href="/ct2/home">Home</a>
            <a style="margin-left:1em;" title="Show Search Page" href="/ct2/search">Search</a>
            <a style="margin-left:1em;" title="Show Study Topics Page" href="/ct2/search/browse">Study Topics</a>
            <a style="margin-left:1em;" title="Show Glossary Page" href="/ct2/info/glossary">Glossary</a>
            <br/>
      <form method="get" action="/ct2/results" style="margin-top:0.5ex; margin-bottom:0px;">
        <input class="body3" type="text" name="term" alt="Quick Search" title="Quick Search" value="" size="30" maxlength="250"/>
        <input class="header3" type="submit" alt="Search" value="Search"/>
        
      </form>
    </td>
  </tr>
</table>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<a name="MainContent" id="skipnav"></a>


<!-- above_tabs -->
<div class="show_back_color">
<br/>


</div>








<!-- tabs -->
<div class="show_back_color header3">
<table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="bottom">
            <td valign="bottom"><img style="width:20px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="fore_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_fore.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_fore.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5ex 1.0em" nowrap >
            <span class="header2">Full Text View</span>
          </td>
          <td align="right"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img width="1" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td/>
          <td align="right"><img width="2" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Tabular View Page" href="/ct2/show/record/NCT00116012" >Tabular View</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show No Study Results Posted Page" href="/ct2/show/results/NCT00116012"  style="color:#666666" >No Study Results Posted</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td valign="bottom"><img style="width:50px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Related Studies Page" href="/ct2/show/related/NCT00116012" >Related Studies</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom" width="100%"><img style="width:100%; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
  </tr>
</table>
</div>

<!-- Title section -->
<div class="indent3" align="center">

    <div class="header1" style="margin-top:3ex;">Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32</div>
  
      <div class="header2" style="margin-top:2ex; color:  red  ">
    This study has been completed.
  </div>
      
  
  <div style="margin-top:2ex">
    First Received: June 26, 2005 &nbsp;
          Last Updated: November 27, 2006 &nbsp;
      <a href="/ct2/archive/NCT00116012"
        title="Historical versions of study NCT00116012 on ClinicalTrials.gov Archive Site"
        onclick="openNewWindow('/ct2/archive/NCT00116012'); return false;">History of Changes</a>
      </div>

  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="50%" style="margin:2ex 0;">

        <tr>
      <th align="right" nowrap class="header3 pale_banner_color"> Sponsor: </th>
      <td align="left" nowrap class="body2"> ARCA Biopharma, Inc. </td>
    </tr>
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">
         Collaborator:       </th>
      <td align="left" nowrap class="body2">
                                         The TIMI Study Group<br/>               </td>
    </tr>
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">Information provided by: </th>
      <td align="left" nowrap class="body2">ARCA Biopharma, Inc.</td>
    </tr>
    
    <tr>
      <th align="right" nowrap class="header3 pale_banner_color">ClinicalTrials.gov Identifier: </th>
      <td align="left" nowrap class="body2">NCT00116012</td>
    </tr>

  </table>

</div>
  
<!-- purpose_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Purpose</span>

<div class="indent2" style="margin-top:2ex">

  <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">The primary focus of this study is to explore the safety of a range of doses of rNAPc2 in subjects who are managed in hospitals that most typically practice an early invasive strategy (catheterization during the index admission). After completion of the ascending dose-ranging part of the trial and review of these data by the Data and Safety Monitoring Board (DSMB), the maximum tolerated dose of rNAPc2 will be studied in single-arm, open-label panels (approximately 25 subjects each) of rNAPc2 with descending doses of unfractionated heparin (UFH).</p></div><br/>

    <!-- condition, intervention, phase summary table -->
  <div align="center">
  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="80%">
    <tr align="left">
            <th class="header3 pale_banner_color">
        <a href="/ct2/help/conditions_desc" title="Help on Conditions field" onclick="openPopupWindow('/ct2/help/conditions_desc',false); return false;">Condition</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">Intervention</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/phase_desc" title="Help on Phase field" onclick="openPopupWindow('/ct2/help/phase_desc',false); return false;">Phase</a>
      </th>
          </tr>
    <tr align="left" valign="top">
            <td class="body3" nowrap>
                Coronary Disease<br/>
              </td>
                  <td class="body3" nowrap>
                Drug: rNAPc2<br/>
              </td>
                  <td class="body3" nowrap>
                Phase II<br/>
              </td>
          </tr>
  </table>
  </div>
  <br/>
  
  
  <table class="layout_table" style="margin-bottom:2ex;" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Study Type:</td>
      <td style="padding-left:1em">
        Interventional
              </td>
    </tr>
            <tr valign="top">
      <td nowrap>Study Design:</td>
      <td style="padding-left:1em">Allocation:&#160;Randomized<br/>Control:&#160;Dose&#160;Comparison<br/>Endpoint&#160;Classification:&#160;Safety/Efficacy&#160;Study<br/>Intervention&#160;Model:&#160;Single&#160;Group&#160;Assignment<br/>Masking:&#160;Open&#160;Label<br/>Primary&#160;Purpose:&#160;Treatment</td>
    </tr>
            <tr valign="top">
      <td nowrap style="padding-top:2ex">Official Title:</td>
      <td style="padding-left:1em; padding-top:2ex">A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment #3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin</td>
    </tr>
      </table>

    <!-- NLM links -->
  <br/>
  <div class="header3">Resource links provided by NLM:</div>
  <br/>
  <div class="indent3">

  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a href="http://www.nlm.nih.gov/medlineplus/" title="MedlinePlus site" onclick="openNewWindow('http://www.nlm.nih.gov/medlineplus/'); return false">MedlinePlus</a> related topics:
            <a style="padding-left:0.5em;" href="/ct2/bye/LQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9pdh9Z6oPlQ7xu61yFXNkWd7E." title="Blood&#160;Thinners at MedlinePlus site" onclick="openNewWindow('/ct2/bye/LQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9pdh9Z6oPlQ7xu61yFXNkWd7E.'); return false">Blood&#160;Thinners</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/9QoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90d-yZdNGST7GSihHST7PewcHkwc8uQoPmdt." title="Coronary&#160;Artery&#160;Disease at MedlinePlus site" onclick="openNewWindow('/ct2/bye/9QoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS90d-yZdNGST7GSihHST7PewcHkwc8uQoPmdt.'); return false">Coronary&#160;Artery&#160;Disease</a>
          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a href="http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp" title="Drug Information Portal" onclick="openNewWindow('http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp'); return false">Drug Information</a> available for:
            <a style="padding-left:0.5em;" href="/ct2/bye/YQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898oyZihHedpm4." title="Protein&#160;C at ChemIDplus site" onclick="openNewWindow('/ct2/bye/YQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd7898oyZihHedpm4.'); return false">Protein&#160;C</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/oQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789HhkSdcLpd-3vB1gWQ7O." title="Thromboplastin at ChemIDplus site" onclick="openNewWindow('/ct2/bye/oQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789HhkSdcLpd-3vB1gWQ7O.'); return false">Thromboplastin</a>
          </div>
  
  <a href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>


  
  <br/>
  
  </div>
  
    <!-- more details -->
  <br/>
  <div class="header3">Further study details as provided by ARCA Biopharma, Inc.:</div>
  <br/>
  <div class="indent3">

        <!-- primary outcomes -->
    <div class="body3">Primary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Evaluation of the effects of a range of doses of rNAPc2 in subjects with non-STE acute coronary syndrome on safety and laboratory parameters from randomization until 7 days after the last dose of study drug<br/>
            </ul>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="body3">Secondary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Evaluation of the effects of a range of doses of rNAPc2 on the presence of ischemia following randomization as identified via continuous ST segment (Holter) monitoring<br/>
            <li style="margin-top:0.7ex;">Evaluation of the effects of a range of doses of rNAPc2 on pharmacodynamic and pharmacokinetic measures<br/>
            <li style="margin-top:0.7ex;">Evaluation of the effects of rNAPc2 on major cardiovascular clinical events over the period from randomization until six months following randomization<br/>
            <li style="margin-top:0.7ex;">Assessment of the ability of rNAPc2 to blunt the release of markers of necrosis<br/>
            <li style="margin-top:0.7ex;">Exploration of the relationship between genetic variation and rNAPc2 efficacy<br/>
            <li style="margin-top:0.7ex;">Evaluation of the efficacy and safety of rNAPc2 with reduced-dose (including no) unfractionated heparin (UFH)<br/>
            </ul>
    </div>
    <br/>
    
    
    <table class="layout_table" style="margin-bottom:3ex;" cellpadding="0" cellspacing="0" border="0">
            <tr valign="top">
        <td nowrap> Estimated  Enrollment:</td>
        <td style="padding-left:1em">300</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Start Date:</td>
        <td style="padding-left:1em">June 2005</td>
      </tr>
                      </table>

    
    
    <a name="desc" id="desc"></a>

    
    
        <!-- detailed description -->
    <span class="header3">Detailed Description:</span>
    <div class="body3"><p style="margin-top:0ex; margin-bottom:1ex;">Acute coronary syndromes (ACS), which include unstable angina and non-ST-elevation (non-STE) myocardial infarction, represent a serious clinical condition affecting over 1,000,000 people in the US alone. The combined rate of death and myocardial infarction (MI) in ACS patients is 8-15% after one month, in spite of the best current therapy including use of low-molecular weight heparins, glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, and an early invasive strategy. Given the high prevalence of the disorder, further improvements in the outcomes in these patients are very desirable.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">It is currently believed that the principle cause of the clinical symptoms characterizing ACS results from the transient thrombotic occlusion of one or more coronary vessels.  Coronary thrombosis is initiated by the exposure of the protein tissue factor (TF), which can be found in the sub-endothelial layer of the blood vessel and is a major component of atherosclerotic gruel.  The exposure of TF following vascular damage or rupture of a coronary atherosclerotic plaque, results in the rapid formation of the enzymatic complex composed of TF and the serine protease factor VIIa (fVIIa/TF).  The fVIIa/TF complex initiates an amplified cascade of proteolytic activation steps resulting in the formation of the serine protease thrombin.  The highly amplified generation of thrombin localized to the site of vascular damage or plaque rupture, coupled with the high-shear rheological environment of the coronary vessel, results in the activation and subsequent aggregation of platelets and the formation of an insoluble matrix of fibrin resulting in a platelet-rich thrombus.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">The critical role of the fVIIa/TF complex in the initiation of coronary thrombosis suggests that it may be an ideal target for inhibitors that will result in an attenuation of thrombin generation and subsequent thrombus formation.  Recombinant nematode anticoagulant protein c2 (rNAPc2) is a novel and potent inhibitor of fVIIa/TF that may improve current therapeutic strategies in reducing the extent of coronary thrombosis and subsequent clinical events in patients diagnosed with ACS.</p></div>
        
  </div>
  
</div>
</div>
  
<!-- eligibility_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
  <img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Eligibility</span><br/>

  <br/>
  <div class="indent2">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0">
            <tr>
        <td nowrap>Ages Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">18 Years to 75 Years</td>
      </tr>
                  <tr>
        <td nowrap>Genders Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">Both</td>
      </tr>
                  <tr>
        <td nowrap>Accepts Healthy Volunteers: &nbsp; </td>
        <td style="padding-left:1em">No</td>
      </tr>
                </table>

    
        <div class="header3" style="margin-top:2ex">Criteria</div>
    <div class="indent2"><p style="margin-top:0ex; margin-bottom:1ex;">Inclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Ages 18 to 75 years inclusive</li>
<li style="margin-top:0.7ex;">Ischemic symptoms lasting &gt;= 5 minutes at rest within the prior 48 hours</li>
<li style="margin-top:0.7ex;">Able to be randomized within 48 hours of recent ischemic events</li>
<li style="margin-top:0.7ex;"><p style="margin-top:0ex; margin-bottom:1ex;">At least one of the following criteria (A, B, or C): A. Elevation of CK-MB or troponin above upper limit of normal OR B. ST segment deviation (depression or transient elevation)  of at least 0.5 mm OR C. TIMI risk score &gt;= 3, defined as three or more of the following:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Age &gt;= 65;</li>
<li style="margin-top:0.7ex;">At least 3 of the following risk factors: hypertension, diabetes mellitus, current smoker (within 1 year), dyslipidemia, family history of premature coronary artery disease (&lt; age 60);</li>
<li style="margin-top:0.7ex;">Known or prior coronary artery stenosis &gt; 50%;</li>
<li style="margin-top:0.7ex;">Daily aspirin use for at least 7 days;</li>
<li style="margin-top:0.7ex;">&gt;= 2 ischemic episodes at rest lasting &gt;= 15 minutes each within the prior 24 hours;</li>
<li style="margin-top:0.7ex;">Elevation of CK-MB OR troponin above upper limit of normal;</li>
<li style="margin-top:0.7ex;">ST segment deviation (depression or transient elevation) of at least 0.5 mm.</li>
</ul>
</li>
<li style="margin-top:0.7ex;">Ability to understand and willingness to give written informed consent</li>
<li style="margin-top:0.7ex;">Planned early invasive strategy in the index hospitalization</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Index event is ST-segment elevation MI or new LBBB</li>
<li style="margin-top:0.7ex;">CABG is planned within 7 days</li>
<li style="margin-top:0.7ex;">ACS is secondary to non-atherosclerotic mechanism (e.g. thyrotoxicosis, anemia)</li>
<li style="margin-top:0.7ex;">Prior participation in ANTHEM-TIMI 32, prior exposure to rNAPc2, or participation in a study with any experimental drug or device within 30 days</li>
<li style="margin-top:0.7ex;">Pregnancy, lactation or use of an intrauterine device (note: women of childbearing potential must have a negative b-HCG)</li>
<li style="margin-top:0.7ex;">Active renal disease, Cr &gt; 4 mg/dl, or history of renal transplantation</li>
<li style="margin-top:0.7ex;">History of a bleeding diathesis or recurrent bleeding episodes</li>
<li style="margin-top:0.7ex;">Medical comorbidities which place subject at risk for hemorrhage, including, but not limited to, prior cerebral hemorrhage, arteriovenous malformation, non-hemorrhagic CVA or TIA, GI bleed, active PUD, advanced liver or renal disease. Major trauma, surgery, CNS, spinal or eye surgery within 6 months, or parenchymal organ biopsy within 14 days.</li>
<li style="margin-top:0.7ex;">Uncontrolled hypertension (SBP &gt; 180, DBP &gt; 100) despite 1 hour of adequate treatment</li>
<li style="margin-top:0.7ex;">Gross hematuria within 1 month unless catheterized and subsequently resolved</li>
<li style="margin-top:0.7ex;">Chronic warfarin (INR &gt; 1.4) or anticipated therapy for warfarin</li>
<li style="margin-top:0.7ex;">Platelet count &lt; 120,000/mm3 at randomization or history of thrombocytopenia (confirm in a blue-top tube using sodium citrate)</li>
<li style="margin-top:0.7ex;">Significant anemia (M: Hg &lt; 11 g/dL, F: Hg &lt; 10 g/dL) at randomization</li>
<li style="margin-top:0.7ex;">Active liver disease or ALT and AST &gt; 3 x ULN not felt to be part of presenting ACS</li>
<li style="margin-top:0.7ex;">Fibrinolytic agent within 24 hours or planned use of fibrinolytics</li>
<li style="margin-top:0.7ex;">Known allergy or intolerance to aspirin</li>
<li style="margin-top:0.7ex;">Known allergy to heparin, enoxaparin or pork-based products</li>
<li style="margin-top:0.7ex;">History of heparin-induced thrombocytopenia (type 1 or 2)</li>
<li style="margin-top:0.7ex;">Any condition for which the investigator feels enrollment in the study would place the subject at unacceptable risk (e.g. substance abuse)</li>
<li style="margin-top:0.7ex;">Part 2 ONLY: Use of LMWH or Xa inhibitor (e.g. Angiomax, Argatroban) &gt;= 12 hours before randomization</li>
</ul></div>
    
  </div>

</div>

  
<!-- location_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Contacts and Locations</span><br/>

<div class="indent2" style="margin-top:2ex">

    Please refer to this study by its ClinicalTrials.gov identifier: NCT00116012<br/>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
  <a name="locn" id="locn"></a>

  
  
    <div class="header3" style="margin-top:2ex">Locations</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
            <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Massachusetts</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Brigham and Women's Hospital</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Boston, Massachusetts, United States  </td></tr>
              </table>
  
  
  <!-- sponsors -->
    <div class="header3" style="margin-top:2ex">Sponsors and Collaborators</div>
    <div class="indent2" style="margin-top:1ex">ARCA Biopharma, Inc.</div>
    <div class="indent2" style="margin-top:1ex">The TIMI Study Group</div>
    
  <!-- investigators -->
    <div class="header3" style="margin-top:2ex">Investigators</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
        <tr>
      <td style="padding:1ex 1em 0px 0px" nowrap>Study Director:</td>
      <td style="padding:1ex 1em 0px 0px" nowrap>Steven Deitcher, MD</td>
            <td style="padding:1ex 1em 0px 0px" nowrap>ARCA Biopharma, Inc.</td>
                </tr>
      </table>
  

</div>
</div>

<!-- more_info_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; More Information</span>

<div class="indent2">
  <br/>


    Additional Information:
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/HQoPWw4lZX-i-iSxui16zdhquBc9m/sVc9mwhGuTD3-67yFQ1Pz" title="Company website" onclick="openNewWindow('/ct2/bye/HQoPWw4lZX-i-iSxui16zdhquBc9m/sVc9mwhGuTD3-67yFQ1Pz'); return false">Company website</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <br/>
  
    No publications provided  by ARCA Biopharma, Inc. <br/>
  <br/>
  
    Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
  <div class="indent2">
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwLKC5cR4n." title="Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E; ANTHEM-TIMI-32 Investigators. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007 Jun 26;49(25):2398-407. Epub 2007 Jun 11." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCwLKC5cR4n.'); return false">Giugliano RP, Wiviott SD, Stone PH, Simon DI, Schweiger MJ, Bouchard A, Leesar MA, Goulder MA, Deitcher SR, McCabe CH, Braunwald E; ANTHEM-TIMI-32 Investigators. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007 Jun 26;49(25):2398-407. Epub 2007 Jun 11.</a>
          </div>
      </div>
  <br/>
  
  
  <table class="layout_table" style="margin-top:1ex" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>ClinicalTrials.gov Identifier:</td>
      <td style="padding-left:1em">
        <a title="Current version of study NCT00116012 on ClinicalTrials.gov" href="http://clinicaltrials.gov/ct2/show/NCT00116012">NCT00116012</a> &nbsp; &nbsp;
        <a href="/ct2/archive/NCT00116012"
          title="Historical versions of study NCT00116012 on ClinicalTrials.gov Archive Site"
          onclick="openNewWindow('/ct2/archive/NCT00116012'); return false;">History of Changes</a>
      </td>
    </tr>
            <tr valign="top">
      <td nowrap>Other Study ID Numbers:</td>
      <td style="padding-left:1em">NUVO-0201, ANTHEM</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study First Received:</td>
      <td style="padding-left:1em">June 26, 2005</td>
    </tr>
                <tr valign="top">
      <td nowrap>Last Updated:</td>
      <td style="padding-left:1em">November 27, 2006</td>
    </tr>
            <tr valign="top">
      <td nowrap>Health Authority:</td>
      <td style="padding-left:1em">United States: Food and Drug Administration</td>
    </tr>
      </table>

  
  <!-- keywords -->
    <br/>
  Keywords provided by ARCA Biopharma, Inc.:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    acute coronary syndrome<br/>
                    rNAPc2<br/>
                    unstable angina<br/>
                    Non-STE myocardial infarction<br/>
                    ST elevation<br/>
                    cardiac enzymes<br/>
                    acute coronary syndromes<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    factor VIIa<br/>
                    tissue factor<br/>
                    nematode anticoagulant protein c2<br/>
                    anticoagulants<br/>
                    thrombin inhibitors<br/>
                    thrombosis<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  <!-- mesh terms -->
    <br/>
  Additional relevant MeSH terms:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Coronary Disease<br/>
                    Coronary Artery Disease<br/>
                    Acute Coronary Syndrome<br/>
                    Myocardial Ischemia<br/>
                    Heart Diseases<br/>
                    Cardiovascular Diseases<br/>
                    Vascular Diseases<br/>
                    Arteriosclerosis<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Arterial Occlusive Diseases<br/>
                    Anticoagulants<br/>
                    Thromboplastin<br/>
                    Hematologic Agents<br/>
                    Therapeutic Uses<br/>
                    Pharmacologic Actions<br/>
                    Hemostatics<br/>
                    Coagulants<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  
  <br/>

    <span class="body3">ClinicalTrials.gov processed this record on March 02, 2011</span><br/>
  
  <br/>

</div>
</div>


<!-- Footer -->
<div class="skip"><a href="#MainContent">Back to top of Main Content</a></div>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<div align="center" class="footer">
  <br/>
  <a href="/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrial.gov%2Fct2%2Fshow%2FNCT00116012" onclick="openPopupWindow('/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrial.gov%2Fct2%2Fshow%2FNCT00116012',true); return false;">Contact Help Desk</a><br/>
  <a href="http://www.lhncbc.nlm.nih.gov">Lister Hill National Center for Biomedical Communications</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a>,<br/>
  <a href="http://www.nih.gov/">U.S. National Institutes of Health</a>,&nbsp;
  <a href="http://www.hhs.gov/">U.S. Department of Health &amp; Human Services</a>,<br/>
  <a href="http://www.usa.gov/">USA.gov</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a>,&nbsp;
  <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a><br/>

  <br/>
  <a href="http://www.nih.gov/"><img alt="U.S. National Institutes of Health" src="/ct2/html/images/frame/nih_logo.gif" border="0"/></a>
  <a href="http://www.nlm.nih.gov/"><img alt="U.S. National Library of Medicine" src="/ct2/html/images/frame/nlm_logo.gif" border="0"/></a>
  <a href="http://www.hhs.gov/"><img alt="U.S. Department of Health &amp; Human Services" src="/ct2/html/images/frame/hhs_logo.gif" border="0"/></a>

  <br/>
  <br/>
  <br/>
  <br/>
  <a href="/ct2/crawl" class="skip">Links to all studies - primarily for crawlers</a>
</div>

<!-- 2011:03:04 03:33:08.430  RRc1Cn0:SRc0xCV:I4Ya2XK -->
</body>
</html>
